Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A1 | P43005 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | KCNA5 | P22460 | 5/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | AGXT | P21549 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3282271 | 0.83 | POLB (0.43) | SLC1A1KCNA5KCNH2GAA | |
| SCHEMBL12706104 | 0.82 | SLC1A1 (0.51) | SLC1A1TAAR1IDO1AGXT | |
| SCHEMBL2477113 | 0.81 | CYP2D6 (0.55) | LMNAKCNA5KCNH2 | |
| SCHEMBL3282231 | 0.81 | SLC1A1 (0.54) | SLC1A1TAAR1KMT2AIDO1AGXT | |
| Hydrochloric Acid SCHEMBL6633931 | 0.80 | CYP2D6 (0.54) | KCNA5KCNH2 | |
| Hydrochloric Acid SCHEMBL4749612 | 0.80 | SLC1A1 (0.53) | SLC1A1TAAR1KMT2AIDO1AGXT | |
| SCHEMBL3284710 | 0.78 | DPP4 (0.63) | KCNA5KCNH2 | |
| SCHEMBL1156843 | 0.77 | DPP4 (0.47) | SLC1A1ROCK1CYP11B1CYP11B2IDO1 | |
| SCHEMBL20476844 | 0.77 | CYP3A4 (0.50) | LMNAKCNH2KMT2A | |
| SCHEMBL7751616 | 0.76 | CYP11B1 (0.42) | KCNA5KCNH2CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2018364-B1 | THERAPEUTIC FLUOROETHYL UREAS | ALLERGAN INC (US) | 2013-08-21 | — | — | EP | disclosed |
| US-7709507-B2 | Therapeutic fluoroethyl ureas | ALLERGAN, INC. (US) | 2010-05-04 | — | — | US | disclosed |
| US-20070270498-A1 | THERAPEUTIC FLUOROETHYL UREAS | ALLERGAN, INC. | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270498-A1 | THERAPEUTIC FLUOROETHYL UREAS | SLC14A1, MAPT, UTS2R | SLC1A1 981/4885LMNA 2047/4885ROCK1 1572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.